Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Subfertility due to anovulation is a common problem in women. First-line oral treatment is with antioestrogens such as clomiphene citrate, but resistance may be apparent with clomiphene. Alternative and adjunctive treatments have been used including tamoxifen, dexamethasone, and bromocriptine. The effectiveness of these is to be determined. OBJECTIVES: To determine the relative effectiveness of antioestrogen agents including clomiphene alone or in combination with other medical therapies in women with subfertility associated with anovulation, possibly caused by polycystic ovarian syndrome. SEARCH METHODS: We conducted a search of the Cochrane Gynaecology and Fertility Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, and CINAHL (all from inception to August 2016) to identify relevant randomised controlled trials (RCTs). We searched the United Kingdom National Institute for Clinical Excellence (NICE) guidelines and the references of relevant reviews and RCTs. We also searched the clinical trial registries for ongoing trials (inception until August 2016). SELECTION CRITERIA: We considered RCTs comparing oral antioestrogen agents for ovulation induction (alone or in conjunction with medical therapies) in anovulatory subfertility. We excluded insulin-sensitising agents, aromatase inhibitors, and hyperprolactinaemic infertility. DATA COLLECTION AND ANALYSIS: Two review authors independently performed data extraction and quality assessment. The primary outcome was live birth; secondary outcomes were pregnancy, ovulation, miscarriage, multiple pregnancy, ovarian hyperstimulation syndrome, and adverse effects. MAIN RESULTS: = 69%; low-quality evidence). If 22% of women in the tamoxifen group had a clinical pregnancy, then between 21% and 35% in the clomiphene citrate group would have a clinical pregnancy. Multiple pregnancy rate There was insufficient evidence of a difference in the chance of a multiple pregnancy between the clomiphene citrate group (OR 2.34, 95% CI 0.34 to 16.04; 3 studies; 567 women; very low-quality evidence). If 0% of women in the tamoxifen group had a multiple pregnancy, then between 0% and 0.5% of women in the clomiphene group would have a multiple pregnancy. OHSSThere were no instances of OHSS in either the clomiphene citrate or the tamoxifen group reported from three studies. Clomiphene citrate with tamoxifen versus tamoxifen alone Clinical pregnancy rateThere was insufficient evidence to determine whether there was a difference between groups (OR 3.32, 95% CI 0.12 to 91.60; 1 study; 20 women; very low-quality evidence). No data were reported for the other outcomes. Other comparisons of interestLimited evidence suggested that compared with a gonadotropin, clomiphene citrate was associated with a reduced chance of a pregnancy, ongoing pregnancy, or live birth, with no clear evidence of a difference in multiple pregnancy rates.The comparison of clomiphene citrate plus medical adjunct versus clomiphene alone was limited by the number of trials reporting the comparison and poor reporting of clinical outcomes relevant to this systematic review and by the number of adjuncts reported (ketoconazole, bromocriptine, dexamethasone, combined oral contraceptive, human chorionic gonadotropin, hormone supplementation). The addition of dexamethasone or combined oral contraceptive suggested a possible benefit in pregnancy outcomes, but findings were very uncertain and further research is required to confirm this.There was limited evidence suggesting that a 10-day regimen of clomiphene citrate improves pregnancy outcomes compared with a 5-day regimen. Data for early versus late regimens of clomiphene citrate were insufficient to be able to make a judgement on differences for pregnancy outcomes. AUTHORS' CONCLUSIONS: We found evidence suggesting that clomiphene citrate improves the chance of a clinical pregnancy compared with placebo, but may reduce the chance of live birth or ongoing pregnancy when compared with a gonadotropin. Due to low event rates, we advise caution interpreting these data.The comparison of clomiphene citrate plus medical adjunctive versus clomiphene alone was limited by the number of trials reporting the comparison. The evidence was very low quality and no firm conclusions could be drawn, but very limited evidence suggested a benefit from adjunctive dexamethasone or combined oral contraceptives. Low-quality evidence suggested that a 10-day regimen of clomiphene citrate improves pregnancy rates compared with a 5-day regimen, but further research is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
The Potential Implications of a PCOS Diagnosis on a Woman's Long-Term Health Using Data Linkage
Hart, R., & Doherty, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3886 · Cited by 391
Induction of Ovulation with MRL/41: Preliminary Report
Greenblatt, R. B. (1961) · JAMA · doi:10.1001/jama.1961.03040410001001 · Cited by 343
A randomized study of dexamethasone in ovulation induction with clomiphene citrate
Daly, D. C., Walters, C. A., Soto-Albors, C. E., Tohan, N., & Riddick, D. H. (1984) · Fertility and Sterility · doi:10.1016/s0015-0282(16)47896-9 · Cited by 129
Comparison of two aromatase inhibitors in women with clomiphene‐resistant polycystic ovary syndrome
Al‐Omari, W. R., Sulaiman, W. R., & Al‐Hadithi, N. (2004) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2003.11.010 · Cited by 113
Aromatase inhibitors in ovulation induction
(2004) · Seminars in Reproductive Medicine · doi:10.1055/s-2004-823028 · Cited by 87
López, E., Joanne, G., Daya, S., Daya, S., Parrilla, J. J., Abad, L., Balasch, J., & Balasch, J. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61273-4 · Cited by 52
Cited by
Bahri Khomami, M., Joham, A. E., Boyle, J. A., Piltonen, T., Silagy, M., Arora, C., Misso, M. L., Teede, H. J., & Moran, L. J. (2019) · Obesity Reviews · doi:10.1111/obr.12829 · Cited by 211
Xu, C., Fan, S., Tian, Y., Liu, F., Furuya-Kanamori, L., Clark, J., Zhang, C., Li, S., Lin, L., Chu, H., et al. (2025) · BMJ · doi:10.1136/bmj-2024-082068 · Cited by 39
Ainehchi, N., Khaki, A., Ouladsahebmadarek, E., Hammadeh, M., Farzadi, L., Farshbaf-Khalili, A., Asnaashari, S., Khamnei, H., Khaki, A. A., & Shokoohi, M. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.93271 · Cited by 31
“CC stimulates ovulation and increases the fertility rate by stimulating GnRH secretion and an anti-estrogenic effect as well [68].”
Background
Metadata
- Authors
- Brown, J., & Farquhar, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-12-15
- Volume
- 2017
- Issue
- 1
- Pages
- CD002249-CD002249
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2561869698
- Cited by
- 99
- References
- 10
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. https://app.cochat.ai/papers/10.1002/14651858.cd002249.pub5
- The paper
- Brown, J., & Farquhar, C. (2016). Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd002249.pub5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.